

## GOOD MANUFACTURING PRACTICE CERTIFICATE

Exporting (certifying) country: **CANADA**  
Importing (requesting) country: **TURKEY**

1. Name and dosage form of the product:  
**SOLUTION**

1.1 Active ingredient(s)<sup>2</sup> and amount(s) per unit dose:<sup>3</sup>

For complete composition including excipients, see attached:<sup>4</sup> **No**

1.2 Is this product licensed to be placed on the market for use in the exporting country?<sup>5</sup> **N/A**  
If YES, continue with section 2A and leave section 2B blank.  
If NO, leave question 1.3 and section 2A blank and continue with section 2B <sup>6</sup>

1.3 Is this product actually on the market in the exporting country? **N/A**  
**THIS CERTIFICATE DOES NOT RELATE TO ANY SPECIFIC PRODUCT.**

2A.1 Number of product license and date of issue:<sup>7</sup>

2A.2 Product license holder (name and address):

2A.3 Status of license holder:<sup>8</sup>

2A.3.1 For categories (B) and (C) the name and address of the manufacturer producing the dosage form is:

2A.4 Is a summary basis for approval appended?<sup>10</sup> **Not Applicable**


2A.5 Is the attached product information complete and consonant with the license?<sup>11</sup> **Not Required**

2A.6 Applicant for certificate, if different from license holder (name and address):

**T.C.**  
**Ottava Büyükelçliği**

İşbu belgede, Kanada yetkili makamlarınca yapılan tasdik işlemindeki  
imza ve mühürün, *Kanada Dışişleri Bakanlığı'na*  
ait olduğu metne şamil olmamak üzere onaylandı **12-2-2021**

Çağdaş MÜHÜR  
Second Secretary  
İkinci Katip



**Declared  
original by:**

**BRANDON ROBERT REINHART**  
Barrister, Solicitor & Notary Public



Health Santé  
Canada Canada

2B.1 Applicant for certificate (name and address):

SAOL THERAPEUTICS RESEARCH LIMITED  
PETER STREET, UNIT G04  
ADELAIDE CHAMBERS, DUBLIN  
DUBLIN 8, IRELAND

CANADIAN REPRESENTATIVE:  
REGCON SOLUTIONS (CANADA) INC.  
359 JANENE COURT  
MISSISSAUGA, ON  
CANADA, L5A 3Z2

2B.2 Status of applicant:<sup>8</sup> C

2B.2.1 For categories (B) and (C) the name and address of the manufacturer producing the dosage form is:

FABRICATING, PACKAGING, LABELLING AND TESTING SITE:  
EMERGENT BIOSOLUTIONS CANADA INC.  
155 INNOVATION DRIVE  
WINNIPEG, MB  
CANADA, R3T 5Y3

2B.3 Why is marketing authorization lacking?

2B.4 Remarks:<sup>13</sup> GMP CERTIFICATE

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? <sup>14</sup> Yes

If NO or NOT APPLICABLE, proceed to question 4

3.1 Periodicity of routine inspections (years): 2

3.2 Has the manufacture of this type of dosage form been inspected? Yes

3.3 Do the facilities & operations conform to GMP as recommended by the WHO? <sup>15</sup> Yes

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product? <sup>16</sup> Yes

If NO, explain:

#### Address of certifying authority

Regulatory Operations and Enforcement Branch  
Health Product Compliance Directorate  
200 Eglantine Driveway, Tunney's Pasture  
Ottawa, Ontario K1A 0K9

Digitally signed by  
Negus, Caitlin  
DN: C=CA,  
OU=HC-SC, O=GC,  
CN="Negus, Caitlin",  
E=caitlin.negus@canada.  
ca

*Caitlin Negus*

Date: 2021-02-02 14:19:

34

Signature: \_\_\_\_\_

Date: 2021-02-01

Name of authorized person **Caitlin Negus**

This certificate expires 1 year from the date of issue







- c. the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;
  - d. the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
  - e. any other reason, please specify.
14. Not applicable means the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
  15. The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series No. 823, 1992, Annex 1. Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).
  16. This section is to be completed when the product-licence holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

Regulatory Operations and Enforcement Branch  
Health Product Compliance Directorate  
Jeanne Mance Bldg, 13<sup>th</sup> Floor  
200 Eglantine Driveway  
Ottawa, ON K1A 0K9  
Mail Stop: 1913C

January 18<sup>th</sup>, 2021

TO WHOM IT MAY CONCERN,


**RE: Health Canada authorized signatories for CPP and GMP Certificates**

This letter authorizes the electronic issuance of a Certificate of Pharmaceutical Product (CPP) or a Good Manufacturing Practices (GMP) Certificate by Health Canada. The purpose of an electronic certificate is to allow Health Canada to meet the requirements of the voluntary agreement set out in the WHO Certification Scheme on the Quality of Pharmaceutical Products during this period where paper-based certificates are unavailable. This certificate provides assurance to importing countries that the pharmaceutical products they will be importing are safe, effective, and of good quality.

A CPP is issued for human drugs (pharmaceutical, biological and radiopharmaceutical) as well as for veterinary drugs (food-producing animals and non-food producing animals).

Electronic versions of these certificates will now be issued to adapt to the current pandemic context and to provide this critical service through an efficient and streamlined process.

As the Director of the Health Product Inspection and Licensing Division within the Health Product Compliance Directorate of Health Canada, I delegate authority to the following individuals to sign electronic CPPs and electronic GMP Certificates and can attest to their identity and responsibilities within Health Canada.

<b>Camille Bienvenue</b>	<b>ESignature</b>
<p>Corporate Regulatory Compliance and Enforcement Advisor/ Conseillère ministérielle en conformité et application de la loi</p> <p>Drug Establishment Licensing Unit/ Unité des licences d'établissement pour les produits pharmaceutiques</p> <p>Health Product Compliance Directorate / ...</p> <p>Health Canada/ Santé Canada</p>	<p>Digitally signed by Bienvenue, Camille DN: C=CA, O=GC, OU=HC-SC, CN="Bienvenue, Camille" Date: 2021-01-08 08:29:24</p> 



<p><b>Caitlin Negus</b></p> <p>Corporate Regulatory Compliance and Enforcement Advisor / Conseillère ministérielle en conformité et application de la loi</p> <p>Drug Establishment Licensing Unit / Unité des licences d'établissement pour les produits pharmaceutiques</p> <p>Health Product Compliance Directorate / ...</p> <p>Health Canada / Santé Canada</p>	<p><b>ESignature</b></p> <p><i>Caitlin Negus</i></p> <p>Digitally signed by Negus, Caitlin DN: C=CA, OU=HC-SC, O=GC, CN="Negus, Caitlin", E=caitlin.negus@canada.ca Date: 2021-01-08 07:39:49</p>
--	---

If a regulatory authority in an importing country has questions with respect to the authenticity, integrity or validity of an electronic certificate issued by Health Canada, they can contact the Drug Establishment Licensing Unit directly at [hc.cpp.questions.sc@canada.ca](mailto:hc.cpp.questions.sc@canada.ca). The Drug Establishment Licensing Unit will respond by providing an exact copy (electronically marked as duplicate) of the electronic certificate directly to the importing authority.

For any further inquiries, please also contact [hc.cpp.questions.sc@canada.ca](mailto:hc.cpp.questions.sc@canada.ca).

Regards,

Dr. Kim Godard

Director, Health Product Inspection and Licensing  
Health Product Compliance Directorate  
Regulatory Operations and Enforcement Branch  
Health Canada